Recommendation Grading
Type Benefit/harm
Evidence
Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
FC
Formal
consensus
H Harms outweigh
benefits
M Moderate Weak
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low
U Benefits/harms
ratio uncertain
Ins Very Low
Brozek JL, Akl EA, Compalati E, et al: Grading quality of evidence and strength of recommendations in
clinical practice guidelines part 3 of 3. e GRADE approach to developing recommendations. Allerg y
66:588-95, 2011
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
gastrointestinal-cancer-guidelines. Copyright © 2020 by American Society of Clinical Oncolog y.
All rights reserved.
ASCOHCC10202a
Abbreviations
atezo + bev, atezolizumab + bevacizumab; AFP, α-fetoprotein; ASCO, American
Society of Clinical Oncolog y; ECOG, Eastern Cooperative Oncolog y Group; EGD,
esophagogastroduodenoscopy; HBV hepatitis B virus; HCC, hepatocellular carcinoma;
HCV, hepatitis C virus; RCT, randomized controlled trial; TKI, tyrosine kinase inhibitor
Source
John D. Gordan, MD, PhD; Erin B. Kennedy, MHSc; Ghassan K. Abou-Alfa, MD, et al.
Systemic erapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol.
2020 Nov 16 doi: 10.1200/JCO.20.02672
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/gastrointestinal-cancer-guidelines.
